Organogenesis Holdings Inc. (ORGO) Stock Rises on Q4 2025 Earnings

Organogenesis Holdings Inc. (ORGO) reported Q4 2025 revenue of $225.6 million, a year-over-year increase of 78.1%, beating the consensus revenue estimate of $176.2 million.

Gross profit: $175.7 million (up 83.8% YoY)

Operating profit: $63.3 million (up 519.3% YoY)

Net income attributable to common shareholders: $31.5 million (up 436.8% YoY)

Diluted earnings per share: $0.24 (up 500.0% YoY; estimate $0.21)

Cost of sales: $49.9 million (up 60.8% YoY)

Operational cash and balance-sheet highlights include:

Cash from operating activities: $39.4 million (up 260.4% YoY)

Purchases of property, plant and equipment: $4.7 million (up 38.4% YoY)

Cash and cash equivalents: $94.3 million (down 30.4% YoY)

Total liabilities: $164.8 million (up 46.4% YoY)

The strong top-line growth and sizable margin expansion translated into earnings that topped expectations, and the stock moved about 2.7% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Organogenesis Holdings Inc. Insider Trading Activity

Organogenesis Holdings Inc. insiders have traded $ORGO stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $ORGO stock by insiders over the last 6 months:

GLENN H NUSSDORF has made 0 purchases and 4 sales selling 500,000 shares for an estimated $2,619,180.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Organogenesis Holdings Inc. Hedge Fund Activity

We have seen 76 institutional investors add shares of Organogenesis Holdings Inc. stock to their portfolio, and 64 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FIRST LIGHT ASSET MANAGEMENT, LLC removed 3,635,091 shares (-48.5%) from their portfolio in Q4 2025, for an estimated $18,829,771
SOLEUS CAPITAL MANAGEMENT, L.P. removed 2,145,748 shares (-17.7%) from their portfolio in Q4 2025, for an estimated $11,114,974
D. E. SHAW & CO., INC. added 1,476,843 shares (+288.7%) to their portfolio in Q4 2025, for an estimated $7,650,046
NORGES BANK added 1,032,700 shares (+1591.2%) to their portfolio in Q4 2025, for an estimated $5,349,386
JANE STREET GROUP, LLC added 793,839 shares (+903.7%) to their portfolio in Q4 2025, for an estimated $4,112,086
ASSENAGON ASSET MANAGEMENT S.A. added 680,392 shares (+14.0%) to their portfolio in Q4 2025, for an estimated $3,524,430
CITADEL ADVISORS LLC added 569,166 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,948,279

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Organogenesis Holdings Inc. Government Contracts

We have seen $143,170 of award payments to $ORGO over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

4569373821!PURAPLY SX 6CM X 9CM: $17,820
PROSTHETICS - SPINAL SURGICAL IMPLANT/WOUND MATRIX: $11,880
4568408592!PURAPLY AM XT EF, 5 LAYER FENESTRATED,: $8,500
4567480630!PURAPLY AM XT 4.91X4.91: $6,800
4568217009!PURAPLY AM XT 4.91X4.91: $5,100

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Organogenesis Holdings Inc. Analyst Ratings

Wall Street analysts have issued reports on $ORGO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 12/15/2025

To track analyst ratings and price targets for Organogenesis Holdings Inc., check out Quiver Quantitative's $ORGO forecast page.